Considering that extensive anti-tumor effects of CDK4/6i, especially the mechanism of action, cell cycle alternation in HER2+ BC (37), and the cyclinD/CDK 4/6 compound are directly downstream of the HER2 pathway (38), it is reasonable to apply CDK4/6i to HER2+ BC. This evidence concerns the gene ERBB2 and neoplasm.